Dasatinib 在頭頸癌的藥理機轉研究
YC Lin - 2014 - ntur.lib.ntu.edu.tw
本論文探討dasatinib 引發頭頸癌細胞凋亡的藥理機轉. 頭頸部鱗狀細胞癌(簡稱頭頸癌)
是一個病程快速且預後不佳的世界性疾病. 表皮生長因子受體(EGFR) 會促進頭頸癌細胞的生長 …
是一個病程快速且預後不佳的世界性疾病. 表皮生長因子受體(EGFR) 會促進頭頸癌細胞的生長 …
Dasatinib 在頭頸癌的藥理機轉研究
林育靖 - 2014 - airitilibrary.com
The mechanism of dasatinib-induced apoptosis of head and neck squamous cell carcinoma
(HNSCC) cells was investigated in this study. HNSCC is a worldwide disease with …
(HNSCC) cells was investigated in this study. HNSCC is a worldwide disease with …
Metformin sensitizes anticancer effect of dasatinib through AMPK-dependent ER stress in head and neck squamous cell carcinoma cells
YC Lin, MH Wu, TT Wei, YC Lin, CC Chen - Cancer Research, 2014 - AACR
Purpose: Head and neck squamous cell carcinoma (HNSCC) is an important endemic
disease in Taiwan with aggressive course and dismal outcome. Dasatinib is a Bcr-bl and Src …
disease in Taiwan with aggressive course and dismal outcome. Dasatinib is a Bcr-bl and Src …
[HTML][HTML] Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress
YC Lin, MH Wu, TT Wei, YC Lin, WC Huang… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Head and neck squamous cell carcinoma (HNSCC) is an important endemic disease in
Taiwan with aggressive course and dismal outcome. Dasatinib is a Bcr-bl and Src kinase …
Taiwan with aggressive course and dismal outcome. Dasatinib is a Bcr-bl and Src kinase …
Dasatinib induces apoptosis in head and neck squamous cell carcinoma cells through down-regulation of epidermal growth factor receptor (EGFR) in vitro and in vivo
YC Lin, MH Wu, TT Wei, SH Chung, KF Chen… - Cancer Research, 2012 - AACR
Background: Head and neck squamous cell carcinoma (HNSCC) is a worldwide disease
with aggressive course and dismal outcome. Dasatinib, a bcr-abl inhibitor, has been …
with aggressive course and dismal outcome. Dasatinib, a bcr-abl inhibitor, has been …
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and …
FM Johnson, B Saigal, M Talpaz, NJ Donato - Clinical cancer research, 2005 - AACR
Purpose: Epithelial tumors, including non–small cell lung cancer (NSCLC) and head and
neck squamous cell carcinoma (HNSCC), present clinical challenges. One potential target …
neck squamous cell carcinoma (HNSCC), present clinical challenges. One potential target …
Metabolic stress played a role in dasatinib-induced EGFR degradation and apoptosis in head and neck cancer.
YC Lin, MH Wu, TT Wei, KF Chen, AL Cheng, CC Chen - Cancer Research, 2013 - AACR
Head and neck squamous cell carcinoma (HNSCC) is a worldwide disease with aggressive
course and dismal outcome. Dasatinib, a Bcr-abl and Src in hibitor, has been approved …
course and dismal outcome. Dasatinib, a Bcr-abl and Src in hibitor, has been approved …
Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro
Y Song, X Sun, WL Bai, WY Ji - European Archives of Oto-Rhino …, 2013 - Springer
A novel drug named Dasatinib is a highly potent ATP-competitive orally active dual Src/Abl
kinase inhibitor with anti-proliferative activity against solid tumors and CML (chronic myeloid …
kinase inhibitor with anti-proliferative activity against solid tumors and CML (chronic myeloid …
Abstract A73: AMPK activation mediates dasatinib-induced EGFR degradation and apoptosis in head and neck cancer
YCL Lin, MH Wu, TT Wei, YC Lin, CC Chen - Cancer Research, 2015 - AACR
Head and neck squamous cell carcinoma (HNSCC) is a worldwide disease with aggressive
course and dismal outcome. Dasatinib, a Bcr-abl and Src in hibitor, has been approved …
course and dismal outcome. Dasatinib, a Bcr-abl and Src in hibitor, has been approved …
Resistance to dasatinib is associated with the activation of Akt in oral squamous cell carcinoma
Objectives: Overexpression and aberrant activation of Src promote the development of oral
squamous cell carcinoma (OSCC), thus therapies targeting Src-related kinases may afford …
squamous cell carcinoma (OSCC), thus therapies targeting Src-related kinases may afford …